

Coverage of whole proteome by structural genomics observed through protein homology modeling database

Kei Yura · Akihiro Yamaguchi · Mitiko Go

Received: 11 May 2006 / Accepted: 8 August 2006 / Published online: 5 December 2006
© Springer Science+Business Media B.V. 2006

Abstract We have been developing FAMSBASE, a protein homology-modeling database of whole ORFs predicted from genome sequences. The latest update of FAMSBASE (<http://daisy.nagahama-i-bio.ac.jp/Famsbase/>), which is based on the protein three-dimensional (3D) structures released by November 2003, contains modeled 3D structures for 368,724 open reading frames (ORFs) derived from genomes of 276 species, namely 17 archaeobacterial, 130 eubacterial, 18 eukaryotic and 111 phage genomes. Those 276 genomes are predicted to have 734,193 ORFs in total and the current FAMSBASE contains protein 3D structure of approximately 50% of the ORF products. However, cases that a modeled 3D structure covers the whole part of an ORF product are rare. When portion of an ORF with 3D structure is compared in three kingdoms of life, in archaeobacteria and eubacteria, approximately 60% of the ORFs have modeled 3D structures covering almost the entire amino acid sequences, however, the percentage falls to about 30% in eukaryotes. When annual differences in the number of ORFs with modeled 3D structure are calculated, the

fraction of modeled 3D structures of soluble protein for archaeobacteria is increased by 5%, and that for eubacteria by 7% in the last 3 years. Assuming that this rate would be maintained and that determination of 3D structures for predicted disordered regions is unattainable, whole soluble protein model structures of prokaryotes without the putative disordered regions will be in hand within 15 years. For eukaryotic proteins, they will be in hand within 25 years. The 3D structures we will have at those times are not the 3D structure of the entire proteins encoded in single ORFs, but the 3D structures of separate structural domains. Measuring or predicting spatial arrangements of structural domains in an ORF will then be a coming issue of structural genomics.

Keywords domain duplication · domain interactions · genome · homology modeling · P-loop · structural genomics

Introduction

Genome sequencing projects provided a huge number of amino acid sequences without functional information (Stein 2001). To discover biological functions of those proteins, both computational predictions and biochemical experiments are necessary (Tsoka and Ouzounis 2000). Most of the proteins perform functions after forming specific 3D structures, and therefore protein 3D structure is one of the most valuable sources of information to predict protein function (Domingues et al. 2000; Xie and Bourne 2005). Protein function prediction based on 3D structures, especially protein surface structures, with evolutionary and/or

K. Yura (✉)
Quantum Bioinformatics Team, Center for Computational Science and Engineering, Japan Atomic Energy Agency, 8-1 Umemidai, Kizu-cho, Souraku-gun, Kyoto 619-0215, Japan
e-mail: yura.kei@jaea.go.jp

A. Yamaguchi · M. Go
Department of Bio-Science, Faculty of Bio-Science, Nagahama Institute of Bio-Science and Technology, 1266, Tamura-cho, Nagahama, Shiga 526-0829, Japan

M. Go
Ochanomizu University, 2-1-1 Otsuka, Bunkyo-ku, Tokyo 112-8610, Japan

physicochemical characteristics have been extensively studied (Lichtarge and Sowa 2002; Campbell et al. 2003; Kinoshita and Nakamura 2003; Laskowski et al. 2003; Ota et al. 2003; Pieper et al. 2006). However, determining protein structures of all the function-unknown proteins for applying these types of study is not practical.

Proteins are classified into a large number of ‘families’ based on the amino acid sequence similarity (Dayhoff 1972), and proteins with similar amino acid sequences are known to have similar 3D structures (Chothia and Lesk 1986), all because the proteins in a family are evolutionary related (Doolittle 1995). Once we have 3D structure of at least one of the proteins in a family, then 3D structures of other proteins in the same family can be computationally deduced by ‘homology modeling’ (Burley 2000; Baker and Sali 2001). Based on this logic, structural genomics (SG) projects, which are to determine protein 3D structures of representatives for each family have been proposed and launched (Vitkup et al. 2001; Brenner 2000; Burley and Bonnano 2002). In homology modeling, corresponding residues between an amino acid sequence of structure unknown protein (target) and that of 3D structure known protein (template) in the same family are determined by sequence alignment and every residue in a template protein is replaced by that in a target protein (Marti-Renoma et al. 2000).

SG projects have been providing new protein structures (Todd et al. 2005; Xie and Bourne 2005; Chandonia and Brenner 2006). Protein Data Bank (PDB) (Berman et al. 2000) now contains more than 390 3D structures for function unknown or hypothetical proteins (Stark et al. 2004). Protein function predictions based on 3D structures determined by SG projects are also in progress (Goldsmith-Fischman and Honig 2003; Liu et al. 2005; Petrey and Honig 2005). There are some projects that focus on a specific species and try to determine the 3D structures of whole proteins encoded in the genome of the species (Kim 2000; Yokoyama et al. 2000; Kim et al. 2003). Those projects provide a considerable number of 3D structures in a single protein family. This results in providing multiple templates for a single protein family and it can improve quality of homology modeling (Contreras-Moreira et al. 2003).

We have developed FAMSBASE; a database for homology modeling 3D structures of whole proteins predicted on whole genome sequences, since 2001 (Yamaguchi et al. 2003; <http://daisy.nagahama-i-bio.ac.jp/Famsbase/>). FAMSBASE contains results of homology modeling by FAMS, a full automatic modeling software (Ogata and Umeyama 2000).

Sequence alignments between whole ORFs and proteins in PDB are based on GTOP (Kawabata et al. 2002).

We report here the update of the database including differences in the amount of structural data from the previous version, estimation of the time that whole ORFs predicted out of genome sequences are covered by homology modeling 3D structures and upcoming issues for utilizing those modeled structures.

Methods

Data update of FAMSBASE

Correspondence between ORFs derived from whole genome sequences and protein amino acid sequences whose 3D structures are known is provided by GTOP database (Kawabata et al. 2002). The update in May 2005 of FAMSBASE is based on February 2004 version of GTOP. Protein 3D structures in PDB by November 2003 are used for homology modeling templates. FAMS (Ogata and Umeyama 2000) is applied by Umeyama et al. to pair-wise alignments between a predicted ORF sequence and an amino acid sequence with known 3D structure, and a 3D structure is modeled. All the results are stored in FAMSBASE.

Assessing annual difference of data in FASBASE

Based on the amount of data in FAMSBASE in 2001 and the amount of increase in the following years, a due year for whole proteome 3D structure models is estimated. Estimation is done residue-wise, not ORF-wise, since modeled structures in FAMSBASE are often limited to structural domains. In this report, structural domains refer to SCOP domains (Andreeva et al. 2004). All ORFs predicted out of genome sequences are divided into soluble and membrane proteins. The division is carried out by SOSUI (Hirokawa et al. 1998), and a protein with one or more transmembrane regions is classified into a membrane protein. The number of residues of whole soluble proteins encoded in the genome sequence (G) of species i is denoted as S_{Gi} , and the number of residues of whole membrane proteins is denoted as M_{Gi} . The number of residues included in modeled 3D structures of soluble and membrane proteins are denoted as $S3_{Gi}$ and $M3_{Gi}$, respectively. For a certain genome G_i , the coverage of modeled 3D structures in whole soluble proteins is then $S3_{Gi}/S_{Gi} \times 100$ and the coverage for whole membrane proteins is $M3_{Gi}/M_{Gi} \times 100$. The coverage is

summarized in different kingdoms of life as in the following equations;

coverage of soluble protein

$$= \sum_{i \in \text{kingdom}} S3_{Gi} / \sum_{i \in \text{kingdom}} S_{Gi} \times 100,$$

coverage of membrane protein

$$= \sum_{i \in \text{kingdom}} M3_{Gi} / \sum_{i \in \text{kingdom}} M_{Gi} \times 100.$$

Both figures are calculated based on the data at the different times of FAMSBASE update, gradients in figures are then calculated, and the figures are extrapolated up to the year that coverage reaches to 100.

It is getting to be known that not all ORFs assume stable 3D structures. Some parts of ORFs are considered to be natively disordered (Oldfield et al. 2005; Dyson and Wright 2005). Hence it is unlikely that coverage by homology modeling reaches to 100. We, therefore, estimate disordered regions in whole ORFs by DisEMBL (Linding et al. 2003) and omit these disordered regions from the calculation.

Non-overlap multiple model structures in single ORFs

Modeled 3D structures in FAMSBASE are often limited to structural domains. To find an ORF of which most of the entire 3D structure is modeled in pieces of structural domains, an ORF covered by non-overlapping three or more modeled 3D structures in eukaryotic genome is surveyed based on the following criteria; (1) 70% or more residues in the ORF are included in one of the modeled 3D structures, (2) the ORF contains three or more non-overlapping modeled structures, and (3) the sequence identity between a template protein and a target domain is no less than 25%. At the time of FAMSBASE building, five model structures are at most built for each ORF (Yamaguchi et al. 2003). Therefore, the expected number of modeled structures in the above criteria is between three and five.

Prediction of domain interfaces

The 3D structure in pieces for a single ORF needs to be assembled to model the entire 3D structure. For this procedure, a prediction of domain interfaces of each 3D structure is needed. A hydrophobicity index based on protein 3D structures is built for domain interface prediction. Hydrophobicity of amino acid residue is

measured by buriedness of a residue inside the protein 3D structures. A representative 4,529 chains in PDB among which sequence identities are less than 30% were selected and solvent accessibility of each residue is calculated on a monomer state. For each amino acid residue type i ($i = 1, \dots, 20$), the number of residue with accessibility no less than b ($=0.0 - 1.0$) is counted ($S_{b,i}$). Database derived hydrophobicity index ($I_{b,i}$) is obtained by;

$$I_{b,i} = -\log_2 \left(\left(S_{b,i} / \sum_i S_{b,i} \right) / \left(S_{0,i} / \sum_i S_{0,i} \right) \right).$$

b is set to 0.15 to maximize the difference of $I_{b,i}$ among different residues. The index has good correlation with Kyte and Doolittle hydrophobicity index (Kyte and Doolittle 1982). The index $I_{0.15,i}$ is assigned to every residue on the surface (accessibility no less than 0.15) of a modeled 3D structure. The hydrophobicity of each residue on a surface of a protein is then obtained by averaging the assigned values of residues within 7.0 Å from the residue in concern. A hydrophobic patch on the surface of the modeled structure is found as a cluster of surface residues with the hydrophobicity no less than 0.0.

Results and discussion

Coverage of whole protein space by homology modeling

The latest update of FAMSBASE at May 2005 uses protein 3D structures deposited to PDB by the end of Nov. 2003 and ORFs predicted from genome sequences deposited by February 2004 (<http://daisy.nagahama-i-bio.ac.jp/Famsbase/>). The latest FAMSBASE contains 1,396,272 modeled 3D structures of 368,724 ORFs derived from 17 archaeobacterial, 130 eubacterial, 18 eukaryotic and 111 phage genomes; in total 276 genomes. Five models at maximum are built for each ORF in FAMSBASE. Those five models are the structure for the same or different regions in the ORF. When multiple models are built for the same region of ORF, we can evaluate the reliability of the model. When the model based on different templates have the similar 3D structures, then the 3D structure would be reliable. When the structures are different, the modeled structure would be less reliable. We further test the quality of modeled 3D structure by ProsaII (Sippl 1993) and find that about 72% of the modeled 3D structures are energetically ranked as

number one and comparable to experimentally determined 3D structures. Some of the structures that fail the test are structures of a part of a large protein, mostly structural domains of large proteins. It is difficult to assess the quality of this type of domain structures, because interfaces of the domain for other parts of the protein are exposed in the modeled structures. Tendency of amino acid residue appearance in the interface is supposed to be different from that at the surface as we discuss down below.

In the genome of 276 species, 734,193 ORFs are predicted. Therefore, in FAMSBASE, 3D structure of 50% (368,724/734,193) of ORFs have been built and stored (Table 1). These are about 47% of ORFs in archaeobacterial genomes, about 52% in eubacterial genomes and about 49% of eukaryotic genomes.

When a modeled 3D structure is counted based on the number of amino acid residues, not on the number of ORFs, a different aspect emerges. Figure 1 shows the percentage of amino acid residues per ORF included in the modeled structures. ORFs without a modeled structure are omitted. Of archaeobacterial and eubacterial genomes, in 60% of ORFs, more than 80% of the residues are included in modeled 3D structures, however, of eukaryotic genomes, only in 30% of ORFs, more than 80% of the residues are included (red and blue sections in Fig. 1). The proportion of residues in modeled 3D structure can be measured by the number of residues in a typical structural domain as shown in SCOP (Andreeva et al. 2004). The average size of protein domain is around 100–150 residues (Copley et al. 2002). In ORFs with modeled structures, a continuous region of residues with one domain or more remains as structure unknown in only about 18% of ORFs of archaeobacterial and eubacterial genomes, whereas in about 60% of ORFs of eukaryotic genomes, the regions with one domain or more remain as structure unknown.




Fig. 1 Percentage of amino acid residues included in modeled 3D structures in each ORF is classified by 10% bins and shown in pie charts. ORFs without a modeled structure are not included. A number of ORFs with modeled structures and an average

Annual difference of model structures

In FAMSBASE of 2001, 38% of amino acid residues in all ORFs of archaeobacterial and 40% of eubacterial genomes were included in modeled 3D structures (Yamaguchi et al. 2003). In the current update of FAMSBASE based on data by around 2004, 42% of amino acid residues in all ORFs in archaeobacterial and 46% of eubacterial genomes are included in modeled structures. In eukaryotic genomes, 24% of amino acid residues in 2003, and 26% in 2004 are included in modeled 3D structures. Those figures can be used to estimate the time when modeled 3D structures of whole proteins predicted from genomes are obtained. The estimation for the time obtaining the whole soluble and membrane proteins are treated separately, because the speed of structure determination for soluble and membrane proteins seems to differ. The assumption for the estimation is that the speed for structure determination would stay the same and no new protein family would appear.

For eubacterial genomes, 72.6% of residues in whole ORFs are predicted by SOSUI (Hirokawa et al. 1998) to encode soluble proteins and 27.4% to encode membrane proteins. This ratio is not so different from the previous prediction by Krogh et al. (2001). Of about 40% of whole eubacterial ORF that were with modeled 3D structures in 2001, approximately 90% were soluble proteins and 10% were membrane proteins. Therefore, about 50% ($=0.40 \times 0.90/0.726$) of the whole soluble proteins were modeled. Of the whole membrane proteins in eubacterial genome, about 15% ($=0.40 \times 0.10/0.274$) were modeled. In 2004, those figures are grown to 57% and 19%, respectively. In eubacterial whole ORFs, about 19.9% of amino acid residues are predicted to be included in disordered region by DisEMBL (Linding et al. 2003). Some of these regions are included in the modeled structures.

length of the ORFs are shown at the center of each pie chart. Sections bordered by thick black lines indicate that the unmodeled region in the ORF is no less than the size of a domain (about 150 residues)

Table 1 Number of ORFs and those with modeled 3D structures in 276 genomes

Species	ORF	Model	%
Archaea			
<i>Archaeoglobus fulgidus</i> DSM4304	2,407	1,233	51.2
<i>Aeropyrum pernix</i> K1	2,694	789	29.3
<i>Halobacterium</i> sp. NRC-1	2,605	1,195	45.9
<i>Methanosarcina acetivorans</i> C2A	4,544	2,124	46.7
<i>Methanocaldococcus jannaschii</i> DSM2661	1,770	875	49.4
<i>Methanopyrus kandleri</i> AV19	1,687	784	46.5
<i>Methanosarcina mazei</i> Goel	3,371	1,634	48.5
<i>Methanothermobacter thermautotrophicus</i>	1,869	998	53.4
<i>Nanoarchaeum equitans</i> Kin4-M	536	264	49.3
<i>Pyrococcus abyssi</i> Orsay	1,784	942	52.8
<i>Pyrobaculum aerophilum</i> IM2	2,605	1,047	40.2
<i>Pyrococcus furiosus</i> DSM 3638	2,065	1,035	50.1
<i>Pyrococcus horikoshii</i> OT3	2,061	879	42.6
<i>Sulfolobus solfataricus</i> P2	2,994	1,365	45.6
<i>Sulfolobus tokodaii</i> 7	2,826	1,228	43.5
<i>Thermoplasma acidophilum</i> DSM1728	1,478	844	57.1
<i>Thermoplasma volcanium</i> GSS1	1,526	839	55.0
sum	38,822	18,075	46.6
Eubacteria			
<i>Aquifex aeolicus</i> VF5	1,553	929	59.8
<i>Nostoc</i> sp. PCC 7120	6,132	2,765	45.1
<i>Agrobacterium tumefaciens</i> C58	5,301	3,017	56.9
<i>A. tumefaciens</i> C58 (Dupont)	5,402	3,028	56.1
<i>Bacillus anthracis</i> str. Ames	5,311	2,463	46.4
<i>Buchnera aphidicola</i> Sg	552	410	74.3
<i>B. aphidicola</i>	507	385	75.9
<i>Bordetella bronchiseptica</i> RB50	4,994	2,934	58.8
<i>Borrelia burgdorferi</i>	1,639	535	32.6
<i>Bacillus cereus</i> ATCC 14579	5,255	2,534	48.2
<i>Candidatus Blochmannia floridanus</i>	583	447	76.7
<i>Bacillus halodurans</i> C-125	4,066	2,127	52.3
<i>Bradyrhizobium japonicum</i>	8,317	4,449	53.5
<i>Bifidobacterium longum</i> NCC2705	1,731	985	56.9
<i>Brucella melitensis</i> 16M	3,198	1,801	56.3
<i>Bordetella parapertussis</i>	4,185	2,525	60.3
<i>B. pertussis</i> Tohama I	3,447	2,179	63.2
<i>Bacillus subtilis</i> 168	4,106	2,153	52.4
<i>Brucella suis</i> 1330	3,264	1,677	51.4
<i>Bacteroides thetaiotaomicron</i> VPI-5482	4,816	2,462	51.1
<i>Buchnera</i> sp. APS	574	436	76.0
<i>Clostridium acetobutylicum</i> ATCC824	3,848	2,053	53.4
<i>Coxiella burnetii</i> RSA 493	2,045	925	45.2
<i>Chlamydomonas reinhardtii</i> GSI	1,005	505	50.2
<i>Caulobacter crescentus</i>	3,737	2,084	55.8
<i>Corynebacterium diphtheriae</i> NCTC13129	2,272	1,165	51.3
<i>Corynebacterium efficiens</i> YS-314	2,998	1,513	50.5
<i>Corynebacterium glutamicum</i> ATCC 13032	3,099	1,554	50.1
<i>Campylobacter jejuni</i>	1,634	893	54.7
<i>Chlamydia muridarum</i> Nigg	911	483	53.0
<i>Clostridium perfringens</i> 13	2,723	1,470	54.0
<i>Chlamydomonas reinhardtii</i> GSI	1,116	495	44.4
<i>Chlamydomonas reinhardtii</i> GSI	1,052	496	47.1
<i>Chlamydomonas reinhardtii</i> GSI	1,069	501	46.9
<i>Chlamydomonas reinhardtii</i> GSI	1,113	501	45.0
<i>Chlorobium tepidum</i> TLS	2,252	1,166	51.8
<i>Clostridium tetani</i> E88	2,432	1,306	53.7
<i>Chlamydia trachomatis</i> D/UW-3/CX	894	485	54.3
<i>Chromobacterium violaceum</i> ATCC 12472	4,385	2,343	53.4
<i>Deinococcus radiodurans</i> R1	3,102	1,579	50.9

Table 1 continued

Species	ORF	Model	%
<i>Escherichia coli</i> K-12 MG1655	4,284	2,398	56.0
<i>E. coli</i> O157:H7	5,447	2,607	47.9
<i>E. coli</i> O157:H7 EDL933	5,449	2,629	48.2
<i>E. coli</i> CFT073	5,379	2,558	47.6
<i>Enterococcus faecalis</i> V583	3,265	1,568	48.0
<i>Fusobacterium nucleatum</i> ATCC 25586	2,067	1,011	48.9
<i>Geobacter sulfurreducens</i> PCA	3,445	1,902	55.2
<i>Gloeobacter violaceus</i> PCC 7421	4,430	2,208	49.8
<i>Haemophilus ducreyi</i> 35000HP	1,717	865	50.4
<i>Helicobacter hepaticus</i> ATCC 51449	1,875	902	48.1
<i>Haemophilus influenzae</i> Rd	1,709	1,038	60.7
<i>Helicobacter pylori</i> 26695	1,566	741	47.3
<i>Helicobacter pylori</i> J99	1,491	747	50.1
<i>Listeria innocua</i> Clip11262	3,043	1,641	53.9
<i>Leptospira interrogans</i> serovar	4,725	1,719	36.4
<i>Lactococcus lactis</i> IL1403	2,266	1,254	55.3
<i>Listeria monocytogenes</i> EGD-e	2,846	1,653	58.1
<i>Lactobacillus plantarum</i> WCFS1	3,009	1,647	54.7
<i>Mycobacterium bovis</i> subsp.	3,920	2,018	51.5
<i>Mycoplasma gallisepticum</i> R	726	371	51.1
<i>Mycoplasma genitalium</i> G37	480	305	63.5
<i>Mycobacterium leprae</i> TN	1,605	918	57.2
<i>Mesorhizobium loti</i> MAFF303099	7,281	3,829	52.6
<i>Mycoplasma penetrans</i>	1,037	472	45.5
<i>Mycoplasma pneumoniae</i> M129	688	333	48.4
<i>Mycoplasma pulmonis</i> UAB CTIP	782	398	50.9
<i>Mycobacterium tuberculosis</i> H37Rv	3,918	2,036	52.0
<i>Mycobacterium tuberculosis</i> CDC1551	4,187	1,990	47.5
<i>Nitrosomonas europaea</i> ATCC 19718	2,461	1,366	55.5
<i>Neisseria meningitidis</i> MC58	2,025	1,016	50.2
<i>Neisseria meningitidis</i> Z2491	2,065	1,025	49.6
<i>Oceanobacillus iheyensis</i> HTE831	3,496	1,892	54.1
<i>Phytoplasma asteris</i> , OY strain	754	423	56.1
<i>Pseudomonas aeruginosa</i> PAO1	5,566	3,206	57.6
<i>Porphyromonas gingivalis</i> W83	1,909	944	49.4
<i>Photobacterium luminescens laumondii</i>	4,683	2,286	48.8
<i>Prochlorococcus marinus</i> MED4	1,712	933	54.5
<i>Prochlorococcus marinus</i> MIT9313	2,265	1,122	49.5
<i>Prochlorococcus marinus marinus</i>	1,882	939	49.9
<i>Pasteurella multocida</i> PM70	2,014	1,237	61.4
<i>Pseudomonas putida</i> KT2440	5,350	2,968	55.5
<i>Pseudomonas syringae</i> pv. tomato str.	5,608	2,938	52.4
<i>Pirellula</i> sp. 1	7,325	2,588	35.3
<i>Rickettsia conorii</i> Malish 7	1,374	572	41.6
<i>Rhodospseudomonas palustris</i>	4,814	2,739	56.9
<i>Rickettsia prowazekii</i> Madrid E	834	498	59.7
<i>Ralstonia solanacearum</i> GMI1000	5,116	2,698	52.7
<i>Streptococcus agalactiae</i>	2,124	1,159	54.6
<i>Streptococcus agalactiae</i> NEM316	2,094	1,174	56.1
<i>Staphylococcus aureus</i> Mu50	2,748	1,451	52.8
<i>Staphylococcus aureus</i> N315	2,624	1,447	55.1
<i>Staphylococcus aureus</i> MW2	2,659	1,410	53.0
<i>Streptomyces avermitilis</i>	7,671	4,001	52.2
<i>Streptomyces coelicolor</i> A3(2)	8,154	4,195	51.4
<i>Staphylococcus epidermidis</i> ATCC 12228	2,485	1,303	52.4
<i>Shigella flexneri</i> 2a 301	4,452	2,306	51.8
<i>Shigella flexneri</i> 2a str. 2457T	4,068	2,159	53.1
<i>Sinorhizobium meliloti</i> 1021	6,205	3,499	56.4
<i>Streptococcus mutans</i> UA159	1,960	1,136	58.0
<i>Shewanella oneidensis</i> MR-1	4,778	2,291	47.9
<i>Streptococcus pneumoniae</i> R6	2,094	1,101	52.6

Table 1 continued

Species	ORF	Model	%
<i>Streptococcus pneumoniae</i> TIGR4	2,043	1,135	55.6
<i>Streptococcus pyogenes</i> SF370	1,696	956	56.4
<i>Streptococcus pyogenes</i> MGAS8232	1,845	996	54.0
<i>Streptococcus pyogenes</i> MGAS315	1,865	986	52.9
<i>Streptococcus pyogenes</i> SSI-1	1,861	976	52.4
<i>Salmonella typhi</i> CT18	4,767	2,347	49.2
<i>Salmonella typhimurium</i> LT2	4,554	2,457	54.0
<i>Salmonella enterica</i> subsp. enterica	4,323	2,263	52.3
<i>Synechocystis</i> sp. PCC 6803	3,167	1,679	53.0
<i>Synechococcus</i> sp. WH 8102	2,517	1,243	49.4
<i>Thermosynechococcus elongatus</i> BP-1	2,475	1,303	52.6
<i>Thermotoga maritima</i> MSB8	1,846	1,051	56.9
<i>Treponema pallidum</i> subsp.	1,031	517	50.1
<i>Thermoanaerobacter tengcongensis</i> MB4T	2,588	1,403	54.2
<i>Tropheryma whipplei</i> TW08/27	783	494	63.1
<i>Tropheryma whipplei</i> str. Twist	808	499	61.8
<i>Ureaplasma urealyticum</i>	611	303	49.6
<i>Vibrio cholerae</i> N16961	3,828	1,971	51.5
<i>Vibrio parahaemolyticus</i> RIMD 2210633	4,832	2,461	50.9
<i>Vibrio vulnificus</i> CMCP6	4,537	2,461	54.2
<i>Vibrio vulnificus</i> YJ016	5,028	2,499	49.7
<i>Wigglesworthia brevipalpis</i>	611	441	72.2
<i>Wolinella succinogenes</i> DSMZ 1740	2,044	1,208	59.1
<i>Xanthomonas axonopodis</i> pv. citri 306	4,427	2,374	53.6
<i>Xanthomonas campestris</i> pv. campestris	4,181	2,287	54.7
<i>Xylella fastidiosa</i> 9a5c	2,832	1,158	40.9
<i>Xylella fastidiosa</i> Temecula1	2,036	1,066	52.4
<i>Yersinia pestis</i> CO92	4,083	2,116	51.8
<i>Yersinia pestis</i> KIM	4,281	2,123	49.6
sum	396,126	206,311	52.1
Eukaryotes			
<i>Arabidopsis thaliana</i>	28,723	14,394	50.1
<i>Caenorhabditis briggsae</i>	14,713	7,063	48.0
<i>Caenorhabditis elegans</i>	22,220	8,841	39.8
<i>Ciona intestinalis</i>	15,865	7,994	50.4
<i>Drosophila melanogaster</i>	18,302	9,541	52.1
<i>Danio rerio</i>	26,587	16,443	61.8
<i>Encephalitozoon cuniculi</i>	1,996	887	44.4
<i>Guillardia theta</i> Nucleomorph	632	307	48.6
<i>Homo sapiens</i> (ENSEMBLE)	28,063	15,467	55.1
<i>Leishmania major</i> Friedlin	173	62	35.8
<i>Mus musculus</i>	24,928	14,382	57.7
<i>Neurospora crassa</i>	10,088	3,800	37.7
<i>Oryza sativa</i>	16,724	4,517	27.0
<i>Plasmodium falciparum</i> 3D7	5,268	1,905	36.2
<i>Rattus norvegicus</i>	28,682	16,740	58.4
<i>Saccharomyces cerevisiae</i>	5,869	2,913	49.6
<i>Schizosaccharomyces pombe</i>	5,261	2,807	53.4
<i>Takifugu rubripes rubripes</i>	37,452	15,202	40.6
sum	291,546	143,265	49.1
Phages/Viruses			
186	46	8	17.4
44AHJD	21	1	4.8
44RR2.8t	252	51	20.2
933W	80	9	11.3
A118	72	9	12.5
A511	11	0	0.0
Aeh1	331	51	15.4
APSE-1	54	6	11.1
B1	11	1	9.1

Table 1 continued

Species	ORF	Model	%
B103	17	4	23.5
Bcep781	61	5	8.2
BF23	8	1	12.5
bIL170	64	2	3.1
bIL285	62	5	8.1
bIL286	61	7	11.5
bIL309	56	6	10.7
bIL310	29	4	13.8
bIL311	22	6	27.3
bIL312	27	3	11.1
BK5-T	63	6	9.5
Bxb1	86	12	14.0
C2	39	2	5.1
Cp-1	28	2	7.1
φCTX	47	4	8.5
D29	79	15	19.0
D3	94	11	11.7
Rb15	49	6	12.2
φg1e	49	6	12.2
GA-1	35	3	8.6
Gh-1	42	12	28.6
H-19B	22	4	18.2
HF2	114	11	9.6
HK022	57	8	14.0
HK620	58	6	10.3
HK97	61	10	16.4
HP1	41	3	7.3
HP2	36	3	8.3
K139	44	4	9.1
KVP40	381	57	15.0
2,389	57	7	12.3
L-413C	40	4	10.0
L5	85	12	14.1
λ	66	18	27.3
A2	61	8	13.1
Mu	53	6	11.3
N15	60	13	21.7
Mycoplasma virus P1	11	0	0.0
Enterobacteria phage P1	11	0	0.0
P2	42	5	11.9
P22	36	9	25.0
P27	58	9	15.5
P335	49	6	12.2
P4	12	2	16.7
P60	80	13	16.3
PA01	34	5	14.7
PaP3	69	8	11.6
φKZ	306	25	8.2
φCh1	98	9	9.2
φYeO3-12	59	13	22.0
φ105	51	8	15.7
φC31	55	8	14.5
φ3626	50	10	20.0
φE125	71	12	16.9
φETA	66	8	12.1
φNIH1.1	55	6	10.9
φPV83	65	9	13.8
φSLT	62	12	19.4
φadh	63	8	12.7
φBT1	55	9	16.4

Table 1 continued

Species	ORF	Model	%
φA1122	50	10	20.0
P68	22	2	9.1
φKMOV	48	11	22.9
PM2	22	1	4.5
PRD1	22	4	18.2
ΨM2	31	1	3.2
ΨM100	37	4	10.8
PY54	67	10	14.9
PZA	27	4	14.8
R1t	50	6	12.0
RB69	256	56	21.9
RB49	272	49	18.0
Rd	47	6	12.8
RM378	146	17	11.6
PVL	62	8	12.9
Sfi11	25	1	4.0
V	53	7	13.2
SIO1	34	6	17.6
Sk1	54	1	1.9
SP6	20	6	30.0
SP βc2	185	33	17.8
SPP1	106	7	6.6
MM1	53	6	11.3
ST64B	56	8	14.3
ST64T	65	9	13.8
7201	46	8	17.4
DT1	47	7	14.9
O1205	57	4	7.0
Sfi19	45	6	13.3
Sfi21	50	9	18.0
Stx2	165	11	6.7
T3	44	10	22.7
T4	278	58	20.9
T7	58	10	17.2
TM4	89	5	5.6
TP901-1	56	7	12.5
Tuc2009	56	7	12.5
UI36	58	5	8.6
VHML	57	8	14.0
VpV262	67	4	6.0
VT2-Sa	82	11	13.4
Wφ	44	4	9.1
Sum	7,699	1073	13.9
Total	734,193	368,724	50.2

These regions are either incorrectly predicted regions or incorrectly modeled regions. Assuming that the disordered regions without modeled 3D structures are correctly predicted, 10.8% of amino acid residues in soluble proteins were disordered and we would never obtain 3D structures of those regions. Then, by extrapolating the coverage of soluble proteins up to 89.2% (100–10.8) with the current growth rate, we can estimate that, by the year 2017, whole soluble proteins encoded in eubacterial genomes can be modeled (Fig. 2). Whole soluble proteins of archaeobacterial genome can be modeled by 2021 and those of eukaryotic genomes, by 2031.




Fig. 2 Annual differences of modeled structures classified by kingdoms of life. The percentage is the number of amino acid residues included in modeled structures over the whole number of residues in predicted sequences for soluble and membrane proteins in each kingdom. (S) stands for soluble proteins and (M) stands for membrane proteins. Some of the residues are predicted to be in a disordered region. The percentage of residues in disordered regions is shown at the top

Orengo et al. (1999) showed percentage of ORFs with protein 3D structures as between 30 and 46% in 1999. The genome sequences known by 1999 were mostly derived from prokaryotic species and the known protein 3D structures were mostly soluble proteins. Therefore, the figures they presented in 1999 should correspond to the figures of archaeobacterial and eubacterial soluble proteins. When we extrapolate the figures of archaeobacterial and eubacterial soluble proteins to the past in Fig. 2, the figures are around 40% in 1999, indicating that their figures approximately lie on the extrapolated lines.

The current estimation indicates that we will obtain 3D structures of whole soluble proteins of eubacteria in 11 years and archaeobacteria in 15 years. This estimation does not take into account the acceleration of structure determination speed by automation (McPherson 2004; DeLucas et al. 2005), which makes the due days closer to the present. For membrane proteins, speed of structure determination has been drastically accelerated by recent technical innovations (Kyogoku et al. 2003; Lundstrom 2004; Walian et al. 2004; Dobrovetsky et al. 2005), and therefore we will not linearly extrapolate the present status to estimate the due day for membrane proteins.

Frequency of template structure in use

When the template 3D structures used in FAMSBASE are classified by SCOP superfamily, which is a group of

proteins that have low sequence identities but whose structural and functional features suggest that a common evolutionary origin is probable (Lo Conte et al. 2002), and frequencies of superfamilies in use are counted, ‘P-loop containing nucleoside triphosphate hydrolases’ superfamily is found to be the most frequent one; 7,532 times (about 12%) in whole archaeobacterial model structures, 77,806 (about 10%) in eubacterial structures and 35,468 times (about 6%) in eukaryotic structures. The templates that follow in frequency in archaeobacterial and eubacterial protein structures are ‘NAD(P)-binding Rossmann fold domains’, ‘4Fe–4S ferredoxin’, and ‘PLP-dependent transferases’ superfamilies. In eukaryotic protein structures, ‘protein-kinase’, ‘immunoglobulin’ and ‘C₂H₂ and C₂HC zinc fingers’ superfamilies, which appear specifically in eukaryotic genomes, follow the top.

Differences in distribution of frequency of templates in different kingdoms of life are evident, when frequencies in use of template are plotted in descending order (Fig. 3). In any kingdoms of life, the frequencies of the most and the second most used templates exceed those of the remaining templates. The frequencies of templates in use drops first in archaeobacterial protein structures and then in eubacterial protein structures. The descending curve of eukaryotic template frequency is less steep compared with the others, indicating that one template can produce a large number of domain 3D structures in eukaryotic ORFs. In other




Fig. 3 Frequency of template usage in descending order. Horizontal axis is a template and the vertical axis is a frequency of templates in use. Red line is a template usage in archaeobacteria, blue line is eubacteria and green line is eukaryotes

words, a significant number of proteins encoded in eukaryotic genomes are originated by domain duplication, as Koonin et al. (2000) demonstrated. Superfamilies with the 3D structures and with many copies in eukaryotic genomes, but seldom in prokaryotic genomes are ‘protein kinase-like’, ‘immunoglobulin’, ‘RNA-binding domain’, ‘C₂H₂ and C₂HC zinc fingers’, ‘WD40-repeat’, ‘glucocorticoid receptor-like’, ‘homeodomain-like’, ‘PH domain-like’, ‘RING-box’, ‘L domain’, ‘ankyrin repeat’, ‘ARM repeat’, ‘cytochrome P-450’ and ‘EF-hand’ superfamilies. These superfamilies are transcription factors, protein–protein interaction mediators and response factor for toxic substances, mostly known to be unique to eukaryotes.

The ‘P-loop containing nucleoside triphosphate hydrolases’ superfamily outnumbering other superfamily in template frequency corresponds to the previous finding that the enzyme is highly frequently used in every kingdom of life (Leipe et al. 2003). When biological functions of these ORFs with the 3D structure of ‘P-loop containing nucleoside triphosphate hydrolases’ superfamily are classified, about half of the proteins are ABC transporters in archaeobacterial and eubacterial proteomes, but numbers of G-proteins and motor proteins in eukaryotic proteomes are noticeable (Fig. 4).

In the last two years, new protein structures were determined and contributed to an increase in the number of templates for homology modeling. A part of those template structures are listed in Table 2. Those top 15 templates contributed a lot for the growth of




Fig. 4 Protein family distribution of ‘P-loop containing nucleoside triphosphate hydrolases’ superfamily in each kingdom. In the three pie charts, the section with the same color is a category of the same family except for the white section

Table 2 Top 15 modeling templates in the newly determined 3D structures between 2002 and 2003

PDBID	Chain	Number of uses as a template	SG ^a	Protein name
1q12	A	7,031	N	Maltose/maltodextrin transport ATP-binding protein MalK
1l2t	A	6,529	N	Hypothetical ABC transporter ATP-binding protein Mj0796
1oxx	K	3,948	N	ABC transporter ATP-binding protein GlcV
1pf4	A	3,202	N	Transport ATP-Binding Protein MsbA
1nr0	A	2,640	Y	Actin interacting protein 1 Aip1
1ixc	A	2,495	N	LysR-type regulatory protein CbnR
1ld8	A	2,410	N	Farnesyltransferase α subunit
1ji0	A	2,331	Y	ABC transporter
1oyw	A	2,251	N	ATP-dependent DNA helicase; RecQ helicase
1kt1	A	2,198	N	Fk506-binding protein FKBP51
1mt0	A	1,961	N	Haemolysin secretion ATP-binding protein; ATP-binding domain
1mdb	A	1,745	N	2,3-dihydroxybenzoate-AMP ligase DhbE
1nnm	A	1,730	N	Acetyl-CoA synthetase
1gxr	A	1,715	N	Transducin-like enhancer protein 1 Esg1
1uoh	A	1,706	N	26S proteasome non-ATPase regulatory subunit 10

^a PDB entry seemingly derived from the SG projects judged by description in PDB file is tagged Y, and the remaining entry is tagged N

modeled 3D structure database. In Table 2, 3D structure derived from SG projects is rare. The ratio of SG products in Table 2 is the same as that in PDB (Editorial Board, Nature Structural & Molecular Biology 2004). As the SG projects in US and Europe have proceeded to phase 2 (Service 2005), SG products are expected to contribute to increase in the number of templates in the near future. The qualities of protein 3D structures, namely, size, resolution, R-factors and so forth, derived from SG projects were compared with those in PDB and no obvious compromise in quality of SG products were found (Todd et al. 2005). The quality of homology modeling based on products of SG projects in the future, therefore, will be expected to be no less than the current quality.

Whole structure and function of proteins from homology modeling of domain structures

Protein function prediction, especially studies on enzyme specificity, based on homology modeling structures is intensively carried out in the field of drug design and related fields (Goldsmith-Fischman and Honig 2003; Kopp and Schwede 2004). Those studies are mostly based on homology modeling of domain structures. As mentioned above, most of the eukaryotic protein structures in FAMSBASE are 3D structures of structural domains, not the entire coding regions (Fig. 1). Protein functional sites are often located at a cleft of domains (Laskowski et al. 1996), and therefore understanding relative location of domains will be a critical issue. Xie and Bourne (2005) and O'Toole et al.

(2003) also pointed out this problem and mentioned, “even if all the domains of a multiple-domain query sequence have determined structures, the individual structures will not enable accurate modeling of how they associate together in the structure of the entire proteins (O'Toole et al. 2003).”

Figure 5 shows all eukaryotic ORFs whose 3D structures are mostly modeled in pieces. There are three types of enzymes and four types of cell surface receptors. A protein structure of ENSP00000264705 which is an ORF found in human genome can be modeled based on *Escherichia coli* carbamoylphosphate synthetase (CPS) and *Pyrococcus abyssi* aspartate transcarbamoylase (ATC). *E. coli* CPS is composed of a large subunit and a small subunit. CPS and ATC are the first and the second enzymes, respectively, in pyrimidine biosynthesis pathway. In mammalian genomes, those proteins are coded by a single gene and active in a hexamer form (Serre et al. 2004). Interactions between the large subunit domain and the small subunit domain of human CPS are conjectured to be the same as those between the large and the small subunits of *E. coli* CPS. N-terminal residues of the large subunit and the C-terminal residues of the small subunit are spatially located close in *E. coli* CPS, which permits the two chains to be chemically connected without disrupting subunit interfaces. To be active, human CPS should form a hexamer supramolecule and the interfaces for the supramolecule formation should be predicted from the modeled 3D structures. At the moment, the interfaces are unknown.




Fig. 5 Eukaryotic ORFs with multiple model structures covering more than 70% of entire protein. In each of the bar representation of proteins, a black box is a region with 3D structure. A name and PDB ID of a template structure and amino acid sequence identity between template and target domains are given below the black box. A yellow box is a

putative signal peptide and green box is a putative transmembrane region. Template and modeled structures of ENSMUSP00000019416 were shown on the right side of the figure. Each domain is colored by hydrophobicity. A hydrophilic residue is in green and a hydrophobic residue is in red. A buried residue is in deep blue

ENSMUSP00000019416 is an ORF found in mouse genome and encodes a putative cell surface receptor. The protein is predicted to consist of six consecutive Ig-fold domains. There is a putative transmembrane helix at the C-terminal region of the protein. Two consecutive Ig-fold domains are modeled without overlap, and no pieces of information for relative orientation of three modeled structures have been found. Information of interaction sites of those domains is required to build the entire structure of the protein and to predict a target molecule of this receptor. Computational analyses of domain interfaces and of protein–protein interfaces have been targets for extensive study for a long time, and some general characteristics have been found. One of them is the hydrophobicity of the interfaces (Wodak and Janin 2002). Hydrophobic clusters on the surface of modeled structures of ENSMUSP00000019416 are

shown in right side of Fig. 5. One of the template structures, Nkp46 ectodomain, has hydrophilic surface (green) around the C-terminal residues of the domain, however the modeled structure has a hydrophobic surface (orange) at the corresponding area. The other template structure, LIR-1 D1D2, has a hydrophilic surface around the N-terminal residues of the domain, however the modeled structure has a hydrophobic surface at the corresponding area. The surfaces uniquely turned into hydrophobic in modeled structures are close to the residues that are chemically bonded in the target protein, and therefore both of the areas likely form interfaces of the two domains. The modeled structure based on LIR-1 D1D2 domain has another hydrophobic surface around the C-terminal residues, which may interact with CD158j-like domain located at the C-terminal side of the domain.

Accuracy of homology modeling

There are at least three major issues that affect accuracy in homology modeling; the best template selection, accuracy of an amino acid sequence alignment between template and target protein sequences and the accuracy of structure building procedure itself (Contreras-Moreira et al. 2005). Accuracy of the alignment is high, when sequence identity of template and target proteins is higher than 30%, and alignment of proteins with identity less than 30% is known to be less reliable, thereby accuracy of homology modeling deteriorates (Kopp and Schwede 2004). FAMS has been shown to construct relatively accurate model structures, even with low sequence identity between template and target sequences in CAFASP2, the homology modeling competition (Iwadate et al. 2001; Yamaguchi et al. 2003). A distribution of sequence identity between amino acid sequences of template and target proteins in FAMSBASE is shown in Fig. 6. Half of the model structures in FAMSBASE rely on alignments of sequence identity less than 20%. Figure 6 suggests that the current 3D structure database does not contain good enough structures for high quality homology modeling. SG projects will eventually provide better template structures, and improvement in target selection, alignment and modeling methods are also in pursuit to overcome the difficulties in homology modeling (John and Sali 2003; Wallace et al. 2005).




Fig. 6 Distribution of sequence identity between template and target amino acid sequences in FAMSBASE

Conclusion

Construction of database of whole genome homology modeling clarified that protein 3D structures of about 50% of the protein coding regions in whole genome can now be modeled. Maintaining the current speed of 3D structure determination, it will take, at most, 11 years to have enough templates to cover whole soluble proteins of eubacterial genomes, and 25 years to cover those of eukaryotic genomes. The current advancement in technologies of protein structure determination is expected to make these due times closer to the present. What we obtain at those times are not the 3D structures of entire proteins, but domain structures in pieces. A homology modeled domain structure is now in use of predicting domain functions, but predicting spatial arrangement of domains in a protein will be an important issue for function prediction.

Acknowledgements This work was supported by a Grant-in-Aid for Scientific Research on Priority Area (C), Genome Information Science from the Ministry of Education, Culture, Sports, Science, and Technology of Japan.

References

- Andreeva A, Howorth D, Brenner SE, Hubbard TJP, Chothia C, Murzin AG (2004) *Nucleic Acids Res* 32:D22
- Baker D, Sali A (2001) *Science* 294:93
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) *Nucleic Acids Res* 28:235
- Brenner SE (2000) *Nat Struct Biol* 7(Suppl):967
- Burley SK (2000) *Nat Struct Biol* 7(Suppl):932
- Burley SK, Bonanno JB (2002) *Annu Rev Genomics Hum Genet* 3:243
- Campbell SJ, Gold ND, Jackson RM, Westhead DR (2003) *Curr Opin Struct Biol* 13:389
- Chandonia J-M, Brenner SE (2006) *Science* 311:347
- Chothia C, Lesk AM (1986) *EMBO J* 5:823
- Contreras-Moreira B, Ezkurdia I, Valencia TA (2005) *FEBS Lett* 579:1203
- Contreras-Moreira B, Fitzjohn PW, Bates PA (2003) *J Mol Biol* 328:593
- Copley RR, Ponting CP, Schultz J, Bork P (2002) *Adv Protein Chem* 61:75
- Dayhoff MO (1972) *Atlas of protein sequence and structure*, vol 5. National Biomedical Research, Foundation Georgetown University, Washington, DC
- DeLucas LJ, Hamrick D, Cosenza L, Nagy L, McCombs D, Bray T, Chait A, Stoops B, Belgovskiy A, William Wilson W (2005) *Prog Biophys Mol Biol* 88:285
- Dobrovetsky E, Lu ML, Andorn-Broza R, Khutoreskaya G, Bray JE, Savchenko A, Arrowsmith CH, Edwards AM, Koth CM (2005) *J Struct Funct Genomics* 6:33
- Domingues FS, Koppenssteiner WA, Sippl MJ (2000) *FEBS Lett* 476:98
- Doolittle RF (1995) *Annu Rev Biochem* 64:287
- Dyson HJ, Wright PE (2005) *Nat Rev Mol Cell Biol* 6:197

- Editorial Board (2004) *Nat Struct Mol Biol* 11:201
- Goldsmith-Fischman S, Honig B (2003) *Protein Sci* 12:1813
- Hirokawa T, Boon-Chieng S, Mitaku S (1998) *Bioinformatics* 14:378
- Iwadate M, Ebisawa K, Umeyama H (2001) *Chem-Bio Infor J* 1:136
- John B, Sali A (2003) *Nucleic Acids Res* 31:3982
- Kawabata T, Fukuchi S, Homma K, Ota M, Araki J, Ito T, Ichiyoshi N, Nishikawa K (2002) *Nucleic Acids Res* 30:294
- Kim S-H, Shin DH, Choi I-G, Schulze-Gahmen U, Chen S, Kim R (2003) *J Struct Funct Genomics* 4:129
- Kim S-H (2000) *Curr Opin Struct Biol* 10:380
- Kinoshita K, Nakamura H (2003) *Curr Opin Struct Biol* 13:396
- Koonin EV, Aravind L, Kondrashov AS (2000) *Cell* 101:573
- Kopp J, Schwede T (2004) *Nucleic Acids Res* 32:D230
- Krogh A, Larsson B, von Heijne G, Sonnhammer EL (2001) *J Mol Biol* 305:567
- Kyogoku Y, Fujiyoshi Y, Shimada I, Nakamura H, Tsukihara T, Akutsu H, Odahara T, Okada T, Nomura N (2003) *Acc Chem Res* 36:199
- Kyte J, Doolittle RF (1982) *J Mol Biol* 157:105
- Laskowski RA, Watson JD, Thornton JM (2003) *J Struct Funct Genomics* 4:167
- Laskowski RA, Luscombe NM, Swindells MB, Thornton JM (1996) *Protein Sci* 5:2438
- Leipe DD, Koonin EV, Aravind L (2003) *J Mol Biol* 333:781
- Lichtarge O, Sowa ME (2002) *Curr Opin Struct Biol* 12:21
- Linding R, Jensen LJ, Diella F, Bork P, Gibson TJ, Russell RB (2003) *Structure* 11:1453
- Liu G, Li Z, Chiang Y, Acton T, Montelione GT, Murray D, Szyperski T (2005) *Protein Sci* 14:1597
- Lo Conte L, Brenner SE, Hubbard TJ, Chothia C, Murzin AG (2002) *Nucleic Acids Res* 30:264
- Lundstrom K (2004) *Curr Opin Drug Discov Devel* 7:342
- Marti-Renom MA, Stuart AC, Fiser A, Sanchez R, Melo F, Sali A (2000) *Annu Rev Biophys Biomol Struct* 29:291
- McPherson A (2004) *J Struct Funct Genomics* 5:3
- Ogata K, Umeyama H (2000) *J Mol Graph Model* 18:258
- Oldfield CJ, Ulrich EL, Cheng Y, Dunker AK, Markley JL (2005) *Proteins* 59:444
- Orengo CA, Pearl FM, Bray JE, Todd AE, Martin AC, Lo Conte L, Thornton JM (1999) *Nucleic Acids Res* 27:275
- Ota M, Kinoshita K, Nishikawa K (2003) *J Mol Biol* 327:1053
- O'Toole N, Raymond S, Cygler M (2003) *J Struct Funct Genomics* 4:47
- Petrey D, Honig B (2005) *Mol Cell* 20:811
- Pieper U, Eswar N, Davis FP, Braberg H, Madhusudhan MS, Rossi A, Marti-Renom M, Karchin R, Webb BM, Eramian D, Shen M-Y, Kelly L, Melo F, Sali A (2006) *Nucleic Acids Res* 34:D291
- Serre V, Penverne B, Souciet JL, Potier S, Guy H, Evans D, Vicart P, Herve G (2004) *BMC Biochem* 5:6
- Service R (2005) *Science* 307:1554
- Sippl MJ (1993) *Proteins Struct Funct Genet* 17:355
- Stark A, Shkumatov A, Russell RB (2004) *Structure (Camb)* 12:1405
- Stein L (2001) *Nat Rev Genet* 2:493
- Todd AE, Marsden RL, Thornton JM, Orengo CA (2005) *J Mol Biol* 348:1235
- Tsoka S, Ouzounis CA (2000) *FEBS Letters* 480:42
- Vitkup D, Melamud E, Moulton J, Sander C (2001) *Nat Struct Biol* 8:559
- Walian P, Cross T, Jap B (2004) *Genome Biol* 5:215
- Wallace IM, Blackshields G, Higgins DG (2005) *Curr Opin Struct Biol* 15:261
- Wodak SJ, Janin J (2002) *Adv Protein Chem* 61:9
- Xie L, Bourne PE (2005) *PLoS Comput Biol* 1:e31
- Yamaguchi A, Iwadate M, Suzuki E, Yura K, Kawakita S, Umeyama H, Go M (2003) *Nucleic Acids Res* 31:463
- Yokoyama S, Hirota H, Kigawa T, Yabuki T, Shirouzu M, Terada T, Ito Y, Matsuo Y, Kuroda Y, Nishimura Y, Kyogoku Y, Miki K, Masui R, Kuramitsu S (2000) *Nat Struct Biol* 7(Suppl):943